Generic Stay May Be Shortened Based Only On Behavior In Trial – Appeals Court
Executive Summary
The 30-month stay of approval on generic products may be shortened if the brand firm delays responding to a patent infringement action, but not for delays in the resolution of the overall patent dispute, the Court of Appeals for the Federal Circuit found
You may also be interested in...
Biovail Says Tiazac Andrx Settlement “Satisfies” FTC; Patent Remains Listed
Biovail's Tiazac patent litigation settlement with Andrx satisfies the Federal Trade Commission's concerns regarding late-listed Tiazac patents, Biovail says
Biovail Says Tiazac Andrx Settlement “Satisfies” FTC; Patent Remains Listed
Biovail's Tiazac patent litigation settlement with Andrx satisfies the Federal Trade Commission's concerns regarding late-listed Tiazac patents, Biovail says
FDA Waxman/Hatch “Moot Court” Will Examine Brand/Generic Legal Positions
FDA's chief counsel will be hosting a "moot court" to receive a thorough briefing on the brand and generic industry arguments about the agency's interpretation of the Waxman/Hatch Act